FOLH1 and metastatic prostate carcinoma: Based on the VISION trial, eligible patients for treatment with Lu‐177‐PSMA‐617 off‐study will generally be those with castrate‐resistant metastatic prostate cancer who have progressed after taxane‐based chemotherapy and have PSMA‐positive metastatic lesion(s) seen on PSMA PET/CT scan with no PSMA PET‐negative lesions that meet certain size criteria.